Short-term effects of erythropoietin on neurodevelopment in infants with cerebral palsy: A pilot study

Brain and Development

Volumn 36, Issue 9, 2014, Pages 764-769

  Lee, Hee Song ^a   Song, Junyoung ^a   Min, Kyunghoon ^a   Choi, Yong Soo ^a   Kim, Sun Mi ^a   Cho, Sung Rae ^b,c   Kim, MinYoung ^a  

^a CHA University   (South Korea)

^b Yonsei University College of Medicine   (South Korea)

^c Yonsei University   (South Korea)

Author keywords

Anti inflammatory effect; Cerebral palsy; Neurodevelopment; Recombinant human erythropoietin

Indexed keywords

RECOMBINANT ERYTHROPOIETIN; ANTIINFLAMMATORY AGENT; EPO PROTEIN, HUMAN; ERYTHROPOIETIN; RECOMBINANT PROTEIN;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; BAYLEY SCALES OF INFANT DEVELOPMENT; CEREBRAL PALSY; CHILD; CLINICAL ARTICLE; CLINICAL FEATURE; DRUG EFFICACY; FEMALE; GROSS MOTOR FUNCTION MEASURE; HOSPITALIZATION; HUMAN; INFANT; LENGTH OF STAY; MALE; MOTOR PERFORMANCE; MULTIPLEX LIGATION DEPENDENT PROBE AMPLIFICATION; NERVE CELL DIFFERENTIATION; NEUROPROTECTION; NUCLEAR MAGNETIC RESONANCE IMAGING; PILOT STUDY; SPASTICITY; TREATMENT OUTCOME; CHILD DEVELOPMENT; CONTROLLED STUDY; DRUG EFFECTS; MOTOR ACTIVITY; PATHOPHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; TIME;

ANTI-INFLAMMATORY AGENTS; CEREBRAL PALSY; CHILD DEVELOPMENT; ERYTHROPOIETIN; FEMALE; HUMANS; INFANT; MALE; MOTOR ACTIVITY; PILOT PROJECTS; RECOMBINANT PROTEINS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84929939525     PISSN: 03877604     EISSN: 18727131     Source Type: Journal    
DOI: 10.1016/j.braindev.2013.11.002     Document Type: Article

References (31)

1. Bax M, Goldstein M, Rosenbaum P, Leviton A, Paneth N, Dan B, et al. Proposed definition and classification of cerebral palsy, April 2005. Dev Med Child Neurol 2005;47:571-6.
2. Patel DR, Greydanus DE, Calles Jr JL, Pratt HD. Developmental disabilities across the lifespan. Dis Mon 2010;56:304-97.
3. Fleiss B, Gressens P. Tertiary mechanisms of brain damage: a new hope for treatment of cerebral palsy? Lancet Neurol 2012;11:556-66.
4. Lin CY, Chang YC, Wang ST, Lee TY, Lin CF, Huang CC. Altered inflammatory responses in preterm children with cerebral palsy. Ann Neurol 2010;68:204-12.
5. Dammann O. Persistent neuro-inflammation in cerebral palsy: a therapeutic window of opportunity? Acta Paediatr 2007;96:6-7.
6. Ness JK, Romanko MJ, Rothstein RP, Wood TL, Levison SW. Perinatal hypoxia-ischemia induces apoptotic and excitotoxic death of periventricular white matter oligodendrocyte progenitors. Dev Neurosci 2001;23:203-8.
7. Goni-de-Cerio F, Alvarez A, Caballero A, Mielgo VE, Alvarez FJ, Rey-Santano MC, et al. Early cell death in the brain of fetal preterm lambs after hypoxic-ischemic injury. Brain Res 2007;1151:161-71.
8. Zhu C, Kang W, Xu F, Cheng X, Zhang Z, Jia L, et al. Erythropoietin improved neurologic outcomes in newborns with hypoxic-ischemic encephalopathy. Pediatrics 2009;124:e218-26.
9. Elmahdy H, El-Mashad AR, El-Bahrawy H, El-Gohary T, El-Barbary A, Aly H. Human recombinant erythropoietin in asphyxia neonatorum: pilot trial. Pediatrics 2010;125:e1135-42.
10. Iwai M, Cao G, Yin W, Stetler RA, Liu J, Chen J. Erythropoietin promotes neuronal replacement through revascularization and neurogenesis after neonatal hypoxia/ischemia in rats. Stroke 2007;38:2795-803.
11. Kaindl AM, Sifringer M, Koppelstaetter A, Genz K, Loeber R, Boerner C, et al. Erythropoietin protects the developing brain from hyperoxia-induced cell death and proteome changes. Ann Neurol 2008;64:523-34.
12. Kumral A, Baskin H, Yesilirmak DC, Ergur BU, Aykan S, Genc S, et al. Erythropoietin attenuates lipopolysaccharide-induced white matter injury in the neonatal rat brain. Neonatology 2007;92:269-78.
13. van der Kooij MA, Groenendaal F, Kavelaars A, Heijnen CJ, van Bel F. Neuroprotective properties and mechanisms of erythropoietin in in vitro and in vivo experimental models for hypoxia/ischemia. Brain Res Rev 2008;59:22-33.
14. Marti HH, Bernaudin M, Petit E, Bauer C. Neuroprotection and angiogenesis: dual role of erythropoietin in brain ischemia. News Physiol Sci 2000;15:225-9.
15. Gonzalez FF, McQuillen P, Mu D, Chang Y, Wendland M, Vexler Z, et al. Erythropoietin enhances long-term neuroprotection and neurogenesis in neonatal stroke. Dev Neurosci 2007;29:321-30.
16. Neubauer AP, Voss W, Wachtendorf M, Jungmann T. Erythropoietin improves neurodevelopmental outcome of extremely preterm infants. Ann Neurol 2010;67:657-66.
17. Statler PA, McPherson RJ, Bauer LA, Kellert BA, Juul SE. Pharmacokinetics of high-dose recombinant erythropoietin in plasma and brain of neonatal rats. Pediatr Res 2007;61:671-5.
18. Wood E, Rosenbaum P. The gross motor function classification system for cerebral palsy: a study of reliability and stability over time. Dev Med Child Neurol 2000;42:292-6.
19. Ketelaar M, Vermeer A, Helders PJ. Functional motor abilities of children with cerebral palsy: a systematic literature review of assessment measures. Clin Rehabil 1998;12:369-80.
20. Tieman BL, Palisano RJ, Sutlive AC. Assessment of motor development and function in preschool children. Ment Retard Dev Disabil Res Rev 2005;11:189-96.
21. Newton NR, Leonard CH, Piecuch RE, Phibbs RH. Neurodevelopmental outcome of prematurely born children treated with recombinant human erythropoietin in infancy. J Perinatol 1999;19:403-6.
22. Ohls RK, Ehrenkranz RA, Das A, Dusick AM, Yolton K, Romano E, et al. Neurodevelopmental outcome and growth at 18 to 22 months' corrected age in extremely low birth weight infants treated with early erythropoietin and iron. Pediatrics 2004;114:1287-91.
23. Farrell F, Lee A. The erythropoietin receptor and its expression in tumor cells and other tissues. Oncologist 2004;9(Suppl. 5):18-30.
24. Fisher DA, Laron Z. The early history of pediatric-endocrinology. Pediatr Endocrinol Rev 2003;1(Suppl 1):66-91.
25. Koury MJ, Bondurant MC. The molecular mechanism of erythropoietin action. Eur J Biochem 1992;210:649-63.
26. Sobh MA, El-Tantawy AE, Said E, Atta MG, Refaie A, Nagati M, et al. Effect of treatment of anaemia with erythropoietin on neuromuscular function in patients on long term haemodialysis. Scand J Urol Nephrol 1992;26:65-9.
27. Spandou E, Soubasi V, Papoutsopoulou S, Karkavelas G, Simeonidou C, Kaiki-Astara A, et al. Erythropoietin prevents hypoxia/ischemia-induced DNA fragmentation in an experimental model of perinatal asphyxia. Neurosci Lett 2004;366:24-8.
28. Wen TC, Rogido M, Peng H, Genetta T, Moore J, Sola A. Gender differences in long-term beneficial effects of erythropoietin given after neonatal stroke in postnatal day-7 rats. Neuroscience 2006;139:803-11.
29. Calapai G, Marciano MC, Corica F, Allegra A, Parisi A, Frisina N, et al. Erythropoietin protects against brain ischemic injury by inhibition of nitric oxide formation. Eur J Pharmacol 2000;401:349-56.
30. Li Y, Lu Z, Keogh CL, Yu SP, Wei L. Erythropoietin-induced neurovascular protection, angiogenesis, and cerebral blood flow restoration after focal ischemia in mice. J Cereb Blood Flow Metab 2007;27:1043-54.
31. Wang L, Zhang Z, Wang Y, Zhang R, Chopp M. Treatment of stroke with erythropoietin enhances neurogenesis and angiogenesis and improves neurological function in rats. Stroke 2004;35:1732-7.